Wegovy Cost in Maryland 2026: Cash Price, Insurance, Medicaid, and Savings Options

What Is the Cash Price of Wegovy in Maryland in 2026?

The retail cash price for Wegovy in Maryland is $1,349 per month in 2026, matching Novo Nordisk's published list price for a four-week supply of semaglutide 2.4 mg auto-injector pens. That figure does not change materially from pharmacy to pharmacy for the brand-name product because Novo Nordisk sets a uniform wholesale acquisition cost. Without insurance or a savings program, a 12-month course runs approximately $16,188.

Why the Price Is That High

Wegovy received FDA approval on June 4, 2021, for chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbidity. See the full prescribing information at accessdata.fda.gov. Unlike older anti-obesity agents, semaglutide 2.4 mg is a GLP-1 receptor agonist delivered by a multi-dose pen device, and manufacturing costs are substantially higher than small-molecule oral drugs. The patent portfolio gives Novo Nordisk pricing power that competitors cannot yet challenge with a generic equivalent.

Dose Escalation and Its Effect on Monthly Cost

Wegovy is titrated over 16 weeks from 0.25 mg weekly to the maintenance dose of 2.4 mg weekly. The FDA label specifies four escalation steps. Because every pen cartridge strength carries roughly the same per-month price, the total annual cost at list price is consistent across the titration period. Patients who cannot tolerate the 2.4 mg dose may remain at 1.7 mg; that dose also costs $1,349/month at list price.

GoodRx and Third-Party Discount Cards

GoodRx and similar coupon platforms do not typically reduce the price of brand-name Wegovy in Maryland. Manufacturer contracts with pharmacy benefit managers restrict coupon stacking. The most reliable savings tool for cash-pay commercially insured patients remains the Novo Nordisk savings card described in a later section of this article.

Does Maryland Medicaid Cover Wegovy?

Maryland Medicaid covers Wegovy for chronic weight management, but a prior authorization (PA) is required. Maryland's HealthChoice managed care program follows CMS guidance on GLP-1 coverage for obesity. Physicians must document a BMI of 30 kg/m² or higher (or 27 kg/m² with a qualifying comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), failure of at least one behavioral weight-loss intervention, and the absence of contraindications.

Prior Authorization Criteria

The Maryland Department of Health has aligned its Medicaid PA requirements closely with the drug's FDA-labeled indications. Required documentation typically includes:

• Body-weight and height measurement confirming BMI eligibility
• Documentation of at least one comorbidity if BMI is 27.0 to 29.9 kg/m²
• Attestation that the prescriber is managing or co-managing the patient's obesity long-term
• Confirmation that the patient has attempted a reduced-calorie diet and increased physical activity

Approval periods are generally 12 months, after which renewal PA requires documented weight loss of at least 5% from baseline. CMS's 2024 final rule on anti-obesity medications under Medicaid provided clearer pathways for state coverage.

Maryland Medicaid Managed Care Plans

Most Medicaid enrollees in Maryland receive benefits through HealthChoice managed care organizations (MCOs) such as CareFirst Community Health Plan, Priority Partners, and Jai Medical Systems. Each MCO may apply slightly different PA forms, but the underlying clinical criteria mirror the state formulary. Patients should contact their MCO's pharmacy services line to confirm the specific PA form number and submission process before the prescriber submits.

Which Commercial Insurance Plans Cover Wegovy in Maryland?

Commercial plan coverage in Maryland varies significantly by employer group and individual policy. The American Heart Association's 2023 scientific statement on obesity pharmacotherapy noted that insurance exclusions for weight-loss drugs remain common despite strong cardiovascular evidence. The SELECT trial (N=17,604) published in the New England Journal of Medicine showed a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg vs. Placebo in patients with pre-existing cardiovascular disease, strengthening the case for insurer coverage. SELECT trial, NEJM 2023.

Large Group Employer Plans

Large self-insured employers in Maryland (those governed by ERISA) set their own formularies. Some include Wegovy on Tier 3 or Tier 4 specialty tiers with 25 to 35% coinsurance after deductible. Others exclude anti-obesity medications entirely. The Maryland Insurance Administration does not regulate self-insured ERISA plans, so state mandates do not apply to this segment.

ACA Marketplace and Small Group Plans

Maryland's ACA marketplace plans, sold through Maryland Health Connection, are subject to state insurance law. Maryland does not currently mandate coverage of anti-obesity medications on marketplace plans, though some carriers include Wegovy voluntarily. A patient should review the plan's Summary of Benefits and Coverage (SBC) under "Obesity Treatment" and call the plan's pharmacy line to confirm Wegovy's tier placement and any step-therapy requirements.

Medicare Part D

Medicare Part D plans were historically prohibited from covering weight-loss drugs. The Treat and Reduce Obesity Act, if enacted, would change this, but as of early 2026 CMS has proposed but not finalized the rule. Maryland residents on Medicare should verify their plan's current formulary. If Wegovy is prescribed for a qualifying cardiovascular indication, some Part D plans may cover it under a cardiovascular drug benefit.

How the Novo Nordisk Savings Card Works in Maryland

The Novo Nordisk Wegovy savings card is the single most effective tool for reducing out-of-pocket costs for commercially insured Maryland patients. Eligible patients with commercial insurance pay as little as $0 for a 28-day supply, up to a program maximum. Novo Nordisk's patient assistance programs are described in detail on the FDA-linked manufacturer page.

Eligibility Rules

The savings card is not available to patients whose primary coverage is a federal or state government program. That exclusion covers Medicare, Medicaid, TRICARE, and the Federal Employees Health Benefits program. Maryland Medicaid patients are therefore not eligible. Patients must be U.S. Residents with a valid prescription. Income limits do not apply to the commercial savings card, though separate income-based programs exist for uninsured patients.

The NovoCare Patient Assistance Program

Uninsured or underinsured Maryland patients who meet income criteria may qualify for the NovoCare Patient Assistance Program, which can provide Wegovy at no cost. NovoCare program details are maintained by Novo Nordisk. Eligibility is determined on a case-by-case basis and generally requires annual household income below 400% of the federal poverty level and no current insurance coverage for the drug.

The table below summarizes the cost pathways for a Maryland patient in 2026 based on coverage status:

| Coverage Status | Monthly Out-of-Pocket Estimate | |---|---| | No insurance, no savings program | $1,349 | | Commercially insured with Novo Nordisk savings card | $0 to $25 (plan-dependent) | | Maryland Medicaid (approved PA) | $0 to $4 copay (HealthChoice tier) | | Medicare Part D (not yet covered for weight loss alone) | $1,349 (full list price) | | Compounded semaglutide 2.4 mg via 503A pharmacy | ~$199 |

Is Compounded Semaglutide 2.4 mg Legal in Maryland?

Compounded semaglutide 2.4 mg is legally available in Maryland through state-licensed 503A compounding pharmacies, at a typical cash price near $199 per month. The FDA placed semaglutide on the shortage list in 2022 and 2023, which allowed 503A and 503B pharmacies to compound it legally. The FDA's shortage-based compounding guidance is published on fda.gov. FDA removed semaglutide injection products from the shortage list in October 2024, and 503B outsourcing facilities were given a wind-down period.

Current 503A Status in Maryland

503A pharmacies compound medications for individual patients based on a valid prescription. As of early 2026, 503A pharmacies in Maryland may still compound semaglutide for an individual patient under a patient-specific prescription. The FDA has stated it intends to exercise enforcement discretion regarding 503A compounding of semaglutide on a case-by-case basis, but the regulatory environment remains in flux. FDA guidance on 503A compounding is available on fda.gov. Patients and prescribers should confirm current FDA enforcement status before initiating a compounded semaglutide prescription.

Quality and Safety Considerations

Brand-name Wegovy uses a proprietary formulation of semaglutide developed and validated through Novo Nordisk's manufacturing process. Compounded versions are not FDA-approved and have not undergone the same bioequivalence testing. A 2023 FDA safety communication warned of adverse events associated with compounded semaglutide products. Patients considering compounded semaglutide should discuss the risk-benefit profile with their prescribing clinician.

Cost Comparison

At approximately $199 per month, compounded semaglutide 2.4 mg costs roughly 85% less than the brand-name list price. For an uninsured Maryland patient with no access to the Novo Nordisk savings card and no Medicaid eligibility, compounded semaglutide through a licensed 503A pharmacy may represent the only financially accessible path to GLP-1 therapy. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy acknowledged that access and cost are major barriers to treatment.

Can Maryland Residents Get Wegovy Through Telehealth?

Telehealth prescribing of Wegovy is permitted in Maryland. A Maryland-licensed physician or advanced practice provider may evaluate a patient via synchronous video visit, confirm BMI eligibility, review comorbidities, and transmit a Wegovy prescription electronically to any Maryland-licensed pharmacy. Maryland adopted permanent telehealth flexibilities after the COVID-19 public health emergency ended. The Maryland Board of Physicians' telehealth guidance is aligned with national standards.

What a Telehealth Visit Typically Covers

A standard telehealth obesity-management visit for Wegovy includes a review of the patient's weight history, comorbidity documentation, medication reconciliation (to rule out contraindications such as personal or family history of medullary thyroid carcinoma or MEN2), and a discussion of the titration schedule. The FDA label lists medullary thyroid carcinoma as a contraindication. Many telehealth platforms also arrange at-home lab work to assess baseline metabolic panel, HbA1c, and thyroid function before the first dose.

Lab and Follow-Up Requirements

Most telehealth providers require follow-up visits at 4 weeks, 12 weeks, and every 12 weeks thereafter to assess tolerability, adjust dose, and document weight-loss response. Gastrointestinal side effects (nausea, vomiting, diarrhea) affect a substantial proportion of patients during titration. In STEP-1 (N=1,961), 44.2% of participants in the semaglutide arm experienced nausea. STEP-1, Ryan DH et al., NEJM 2021. Telehealth clinicians typically provide dose-adjustment protocols to manage tolerability.

The Clinical Evidence Supporting Wegovy at $1,349/Month

The price is high. The efficacy data are also substantial. Understanding the trial results helps Maryland patients and their clinicians decide whether the cost is justified given available coverage options.

STEP-1 Trial Results

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks, compared with 2.4% in the placebo group (P<0.001). Ryan DH, Lingvay I, Deanfield J, et al. NEJM 2021. Approximately 86.4% of patients in the semaglutide group achieved at least 5% weight loss, and 69.1% achieved at least 10%.

SELECT Trial Cardiovascular Data

SELECT (N=17,604) enrolled adults with pre-existing cardiovascular disease and overweight or obesity but without diabetes. Semaglutide 2.4 mg reduced the incidence of major adverse cardiovascular events by 20% vs. Placebo over a median follow-up of 34.2 months. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. NEJM 2023. The FDA approved an updated label reflecting this cardiovascular benefit in March 2024, which has since influenced payer coverage discussions.

Endocrine Society Guideline Recommendations

The Endocrine Society's 2023 clinical practice guideline states: "We recommend using pharmacological therapy as an adjunct to lifestyle intervention in patients with obesity (BMI >30 kg/m²) or overweight (BMI 27.0 to 29.9 kg/m²) with weight-related complications." Endocrine Society CPG, JCEM 2023. This recommendation directly supports the clinical rationale for Wegovy prescriptions in Maryland patients who meet the criteria.

Cheapest Ways to Get Wegovy in Maryland: A Practical Comparison

Several distinct pathways exist for Maryland residents trying to minimize out-of-pocket cost.

Path 1: Commercial Insurance Plus Savings Card

For patients with employer-sponsored or ACA marketplace insurance that covers Wegovy, the Novo Nordisk savings card brings monthly cost to near zero. This combination is financially optimal and maintains access to the FDA-approved product. The prescriber should confirm formulary coverage and submit any required PA before writing the prescription.

Path 2: Maryland Medicaid With PA

Medicaid-eligible Maryland patients who qualify clinically can receive Wegovy at a copay of $0 to $4 per month after PA approval. Maryland HealthChoice formulary information is maintained by the Maryland Department of Health. The PA process takes 3 to 10 business days on average. Denials can be appealed, and prescribers should include objective weight and comorbidity data in the initial submission to reduce denial risk.

Path 3: Compounded Semaglutide Through a Licensed 503A Pharmacy

For uninsured patients who do not qualify for Medicaid and cannot access the savings card (e.g., Medicare beneficiaries), compounded semaglutide through a Maryland-licensed 503A pharmacy at approximately $199 per month may be the most accessible option. FDA guidance on 503A pharmacies is available on fda.gov. The prescriber must write a patient-specific compound prescription; it cannot be filled by a 503B outsourcing facility under current FDA enforcement guidance for non-shortage periods.

Path 4: NovoCare Patient Assistance

Uninsured patients below 400% of the federal poverty level may receive Wegovy at no cost through NovoCare. Application processing takes 2 to 4 weeks. NovoCare eligibility and application information. This path preserves access to the FDA-approved drug rather than a compounded version.

Side Effects Maryland Prescribers Monitor Closely

Wegovy's tolerability profile directly affects adherence, and poor adherence negates any cost savings. The FDA prescribing information details contraindications and warnings. The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. In STEP-1, 4.5% of semaglutide participants discontinued due to gastrointestinal adverse events, compared with 0.8% in the placebo group. STEP-1, NEJM 2021.

Rare but serious risks include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumors observed in rodent studies. The FDA label carries a boxed warning for thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Wegovy. Maryland telehealth providers typically screen for these contraindications during the initial video evaluation.

A 2023 systematic review in The Lancet Diabetes and Endocrinology confirmed that GLP-1 receptor agonists are associated with an increased risk of cholelithiasis requiring surgery compared with placebo. Maryland clinicians managing patients on Wegovy should counsel on biliary symptoms and consider baseline abdominal ultrasound in patients with prior gallbladder disease.

Weight Regain After Stopping Wegovy: What Maryland Patients Should Know

Stopping Wegovy is associated with substantial weight regain. STEP-4 (N=803) showed that participants who discontinued semaglutide 2.4 mg after 20 weeks of treatment regained two-thirds of their prior weight loss over the subsequent 48 weeks, while those who continued lost an additional 7.9% of body weight. STEP-4, Rubino DM et al., JAMA 2021. This finding has direct implications for how Maryland patients and payers should think about Wegovy as a long-term, continuous treatment rather than a short-term intervention.

The Obesity Society's position statement on anti-obesity pharmacotherapy states that "obesity is a chronic disease requiring long-term treatment." A Maryland patient who starts Wegovy at $0 per month via the savings card should discuss with their clinician what happens to cost and access if their insurance changes, since sustained treatment is necessary to maintain weight loss.